

**ZYDUS PHARMACEUTICALS UK LIMITED [UK]**  
**Balance Sheet as at March 31, 2024**

Particulars	Note No.	GBP-Thousand
		As at March 31 2024
<b>ASSETS:</b>		
<b>Non-Current Assets:</b>		
Property, Plant and Equipment	1	1
<b>Financial Assets:</b>		
Investments	2	46,585
Loans	3	22,153
		68,740
<b>Current Assets:</b>		
<b>Financial Assets:</b>		
Cash and Cash Equivalents	4	795
Bank balance other than cash and cash equivalents	4	2
Other Current Assets	5	279
		1,076
<b>Total</b>		<b>69,816</b>
<b>EQUITY AND LIABILITIES:</b>		
<b>Equity:</b>		
Equity Share Capital	6	69,900
Other Equity	7	(2,551)
		67,349
<b>Current Liabilities:</b>		
<b>Financial Liabilities:</b>		
Trade Payables	8	2,454
Other Current Liabilities	9	12
		2,466
<b>Total</b>		<b>69,816</b>

**Statement of Profit and Loss for the year ended March 31, 2024**

Particulars	Note No.	GBP-Thousand
		Year ended March 31 2024
Other Income	10	29
<b>Total Income</b>		<b>29</b>
<b>EXPENSES:</b>		
Employee Benefits Expense	11	155
Finance Costs	12	765
Other Expenses	13	1,661
<b>Total Expenses</b>		<b>2,580</b>
<b>Loss before Tax</b>		<b>(2,551)</b>
Less: Tax Expense:		
Current Tax		-
Deferred Tax		-
		-
<b>Loss for the year</b>		<b>(2,551)</b>

For and on behalf of the Board

Sd/-

Director  
Dated : May 15, 2024

**ZYDUS PHARMACEUTICALS UK LIMITED [UK]**  
**Notes to the Financial Statements**

**Note: 1-Property, Plant & Equipment and Intangible Assets:**

	GBP-Thousand
	As at March 31
	2024
<b>Plant and Equipments:</b>	
Gross Block:	
As at March 31, 2023	-
Additions	1
Disposals	-
As at March 31, 2024	1
Depreciation and Impairment:	
As at March 31, 2023	-
Depreciation for the year	0
Disposals	-
As at March 31, 2024	0
Net Block:	
As at March 31, 2023	-
As at March 31, 2024	1

**Note: 2-Investments [Non-Current]:**

Investments in Subsidiaries and Joint Ventures:	
Investments in Equity Instruments	46,585
<b>Total</b>	<b>46,585</b>

**Note: 3-Loans:**

[Unsecured, Considered Good unless otherwise stated]	
Loans and Advances to Related Parties	22,153
<b>Total</b>	<b>22,153</b>

**Note: 4-Cash and Bank Balances:**

<b>A Cash and Cash Equivalents:</b>	
Balances with Banks	795
<b>Total</b>	<b>795</b>
<b>B Bank balance other than cash and cash equivalents:</b>	
Balances with Banks	2
<b>Total</b>	<b>2</b>

**Note: 5-Other Current Assets:**

[Unsecured, Considered Good]	
Balances with Statutory Authorities	279
<b>Total</b>	<b>279</b>

**Note: 6-Equity Share Capital:**

<b>Issued, Subscribed and Paid-up:</b>	
Equity Shares	69,900
	<b>69,900</b>

**Note: 7-Other Equity:**

<b>Retained Earnings:</b>	
Balance as per last Balance Sheet	-
Add [Less]: Profit [Loss] for the year	(2,551)
<b>Balance as at the end of the year</b>	<b>(2,551)</b>

**Note: 8-Trade Payables:**

Others	2,454
<b>Total</b>	<b>2,454</b>

**Note: 9-Other Current Liabilities:**

Payable to Statutory Authorities	12
<b>Total</b>	<b>12</b>

**ZYDUS PHARMACEUTICALS UK LIMITED [UK]**  
**Notes to the Financial Statements**

	GBP-Thousand
	Year ended
	March 31
	2024
<b>Note: 10-Other Income:</b>	
Interest Income	29
<b>Total</b>	<b>29</b>
<b>Note: 11-Employee Benefits Expense:</b>	
Salaries and wages	155
Staff welfare expenses	0
<b>Total</b>	<b>155</b>
<b>Note: 12-Finance Cost:</b>	
Bank commission & charges	765
<b>Total</b>	<b>765</b>
<b>Note: 13-Other Expenses:</b>	
Rent	1
Traveling Expenses	15
Legal and Professional Fees	1,373
Other marketing expenses	270
Miscellaneous Expenses	1
<b>Total</b>	<b>1,661</b>

**ZYDUS PHARMACEUTICALS UK LIMITED [UK]**  
**Cash Flow Statement for the year ended March 31, 2024**

Particulars	GBP-Thousand	
	Year ended March 31	
	2024	
<b>A Cash flows from operating activities:</b>		
[Loss] before tax		(2,551)
Adjustments for:		
Interest income	(29)	
Total		(29)
		(2,580)
Operating profit before working capital changes		
Adjustments for:		
[Increase] in other assets	(281)	
Increase in trade payables	2,454	
Increase in other liabilities	12	
Total		2,185
Net cash [used in] operating activities		(395)
<b>B Cash flows from investing activities:</b>		
Purchase of property, plant and equipment	(1)	
Purchase of non current investments in subsidiaries	(46,585)	
Loans to subsidiaries	(22,152)	
Interest received	29	
Net cash [used in] investing activities		(68,709)
<b>C Cash flows from financing activities:</b>		
Proceeds from Issue of Shares	69,900	
Net cash from financing activities		69,900
<b>Net increase in cash and cash equivalents</b>		<b>797</b>
<b>Cash and cash equivalents at the beginning of the year</b>		<b>-</b>
<b>Cash and cash equivalents at the end of the year</b>		<b>797</b>

**Notes to the Cash Flow Statement**

1 All figures in brackets are outflows.

For and on behalf of the Board

Sd/-

Director

Dated : May 15, 2024